Barinthus Biotherapeutics (NASDAQ:BRNS) Given “Buy” Rating at HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 218.73% from the company’s previous close.

Separately, William Blair reissued an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Monday, January 8th.

Barinthus Biotherapeutics Trading Down 7.4 %

Shares of BRNS traded down $0.20 during midday trading on Friday, hitting $2.51. The stock had a trading volume of 3,323 shares, compared to its average volume of 19,738. The firm has a 50 day moving average of $2.69. Barinthus Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $5.10. The firm has a market capitalization of $97.69 million, a price-to-earnings ratio of -1.35 and a beta of -0.52.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.10. On average, sell-side analysts predict that Barinthus Biotherapeutics will post -2.6 earnings per share for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.